Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13204428 | 1.00 | BRD4 (0.38) | BRD4LMNANPSR1GAAKMT2A | |
| SCHEMBL10116138 | 0.84 | CCR8 (0.43) | LMNAGAAKMT2ATHRBPOLB | |
| SCHEMBL10114925 | 0.83 | GRIA2 (0.35) | BRD4LMNANPSR1KMT2AGRIA2 | |
| SCHEMBL13204424 | 0.83 | GRIA2 (0.35) | BRD4LMNANPSR1KMT2AGRIA2 | |
| SCHEMBL14418515 | 0.82 | GRIA2 (0.39) | BRD4LMNAKDM4EGRIA2ALDH1A1 | |
| SCHEMBL14424390 | 0.82 | GRIA2 (0.39) | BRD4LMNAKDM4EGRIA2ALDH1A1 | |
| SCHEMBL17090544 | 0.82 | MAPK14 (0.37) | KMT2AGRIA2L3MBTL1NR3C1 | |
| SCHEMBL14424261 | 0.80 | NPSR1 (0.48) | LMNANPSR1GAAKMT2AGRIA2 | |
| SCHEMBL10114813 | 0.80 | NPSR1 (0.48) | LMNANPSR1GAAKMT2AGRIA2 | |
| SCHEMBL13204439 | 0.79 | SMN1; SMN2 (0.42) | GAAKMT2AKDM4EGRIA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | BRD4 1776/4885LMNA 2068/4885NPSR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.